Compounds > 2,2'-bipyridyl-6-carbothioamide
Page last updated: 2024-12-10

2,2'-bipyridyl-6-carbothioamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2,2'-bipyridyl-6-carbothioamide: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID3034633
CHEMBL ID17755
SCHEMBL ID5997996
MeSH IDM0103358

Synonyms (16)

Synonym
nsc-308938
nsc308938
78797-02-1
6-(2-pyridyl)pyridine-2-carbothioamide
bpyta
[2,2'-bipyridine]-6-carbothioamide
CHEMBL17755
6-pyridin-2-ylpyridine-2-carbothioamide
hq16m0gm8a ,
nsc 308938
2,2'-bipyridyl-6-carbothioamide
(2,2'-bipyridine)-6-carbothioamide
unii-hq16m0gm8a
DTXSID10229306
SCHEMBL5997996
2,2'-bipyridine-6-thioamide

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Of these, only 2,2'-bipyridyl-6-carbothioamide (1a) showed antitumor activity at relatively high dosage levels."( N*-N*-S* tridentate ligand system as potential antitumor agents.
Antonini, I; Claudi, F; Cristalli, G; Franchetti, P; Grifantini, M; Martelli, S, 1981)		0.61
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (14)

Assay IDTitleYearJournalArticle
AID153150Antitumor activity against P-388 lymphocytic leukemia implanted CDF1 mice to that of control when 100 mg/kg compound administered1981Journal of medicinal chemistry, Oct, Volume: 24, Issue:10
N*-N*-S* tridentate ligand system as potential antitumor agents.
AID97738Growth inhibition of cultured L-1210 cells after 48-h exposure to compound at 4 x 10E-9 M/mL in trail 21981Journal of medicinal chemistry, Oct, Volume: 24, Issue:10
N*-N*-S* tridentate ligand system as potential antitumor agents.
AID97737Growth inhibition of cultured L-1210 cells after 48-h exposure to compound at 4 x 10E-9 M/mL in trail 11981Journal of medicinal chemistry, Oct, Volume: 24, Issue:10
N*-N*-S* tridentate ligand system as potential antitumor agents.
AID154371Change in body weight of P-388 lymphocytic leukemia implanted CDF1 mice to that of control when 100 mg/kg compound administered; T/C=1.5/0.51981Journal of medicinal chemistry, Oct, Volume: 24, Issue:10
N*-N*-S* tridentate ligand system as potential antitumor agents.
AID201713Growth inhibition of cultured Sarcoma cells after 48-h exposure to compound at 4 x 10E-9 M/mL in trail 11981Journal of medicinal chemistry, Oct, Volume: 24, Issue:10
N*-N*-S* tridentate ligand system as potential antitumor agents.
AID201712Growth inhibition of cultured Sarcoma 180 cells after 48-h exposure to compound at 1.6 x 10E-8 M/mL in trail 21981Journal of medicinal chemistry, Oct, Volume: 24, Issue:10
N*-N*-S* tridentate ligand system as potential antitumor agents.
AID153152Antitumor activity against P-388 lymphocytic leukemia implanted CDF1 mice to that of control when 400 mg/kg compound administered1981Journal of medicinal chemistry, Oct, Volume: 24, Issue:10
N*-N*-S* tridentate ligand system as potential antitumor agents.
AID97735Growth inhibition of cultured L-1210 cells after 48-h exposure to compound at 1.6 x 10E-8 M/mL in trail 11981Journal of medicinal chemistry, Oct, Volume: 24, Issue:10
N*-N*-S* tridentate ligand system as potential antitumor agents.
AID154364Change in body weight of P-388 lymphocytic leukemia implanted CDF1 mice to that of control when 200 mg/kg compound administered; T/C=1.5/0.51981Journal of medicinal chemistry, Oct, Volume: 24, Issue:10
N*-N*-S* tridentate ligand system as potential antitumor agents.
AID154365Change in body weight of P-388 lymphocytic leukemia implanted CDF1 mice to that of control when 400 mg/kg compound administered; T/C= -0.8/51981Journal of medicinal chemistry, Oct, Volume: 24, Issue:10
N*-N*-S* tridentate ligand system as potential antitumor agents.
AID201714Growth inhibition of cultured Sarcoma cells after 48-h exposure to compound at 4 x 10E-9 M/mL in trail 21981Journal of medicinal chemistry, Oct, Volume: 24, Issue:10
N*-N*-S* tridentate ligand system as potential antitumor agents.
AID97736Growth inhibition of cultured L-1210 cells after 48-h exposure to compound at 1.6 x 10E-8 M/mL in trail 21981Journal of medicinal chemistry, Oct, Volume: 24, Issue:10
N*-N*-S* tridentate ligand system as potential antitumor agents.
AID153151Antitumor activity against P-388 lymphocytic leukemia implanted CDF1 mice to that of control when 200 mg/kg compound administered1981Journal of medicinal chemistry, Oct, Volume: 24, Issue:10
N*-N*-S* tridentate ligand system as potential antitumor agents.
AID201711Growth inhibition of cultured Sarcoma 180 cells after 48-h exposure to compound at 1.6 x 10E-8 M/mL in trail 11981Journal of medicinal chemistry, Oct, Volume: 24, Issue:10
N*-N*-S* tridentate ligand system as potential antitumor agents.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (20.00)18.7374
1990's4 (80.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.94

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.94 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.88 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.94)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (16.67%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (83.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
2,2'-dipyridyl
2,2'-Dipyridyl: A reagent used for the determination of iron.. 2,2'-bipyridine : A bipyridine in which the two pyridine moieties are linked by a bond between positions C-2 and C-2'.		4.1750bipyridinechelator;
ferroptosis inhibitor
deferoxamine
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.. desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.		1.9810acyclic desferrioxaminebacterial metabolite;
ferroptosis inhibitor;
iron chelator;
siderophore
hydroxyurea
[no description available]		1.9710one-carbon compound;
ureas		antimetabolite;
antimitotic;
antineoplastic agent;
DNA synthesis inhibitor;
EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor;
genotoxin;
immunomodulator;
radical scavenger;
teratogenic agent
ConditionIndicatedRelationship StrengthStudiesTrials
Leukemia P388
An experimental lymphocytic leukemia originally induced in DBA/2 mice by painting with methylcholanthrene.		02.6630
Benign Neoplasms
[description not available]		02.9110
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		02.9110